BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Navigenics Names Vance Vanier, MD, to Serve as President and Chief Executive Officer


1/21/2010 6:48:03 AM

Bookmark and Share

FOSTER CITY, Calif.--(BUSINESS WIRE)--Navigenics, a leading personal genomics company, announced today that Vance Vanier, MD, has been appointed by the Board of Directors to serve as President and Chief Executive Officer of the firm.

Dr. Vanier joined Navigenics as Chief Medical Officer in April of 2008 and has been instrumental in growing the company’s clinical offerings as well as institutional research and corporate partnerships. Prior to joining Navigenics, he was a partner at venture capital firm, Mohr Davidow Ventures where he spent years in the molecular diagnostics industry bringing new genomic technologies into clinical practice. Vanier also serves as a clinical faculty member of Stanford University Medical Center.

“Navigenics has defined preventive genomics and its potential to enable prevention and motivate behavior change, and I look forward to leading the company as it continues to pioneer in this emerging industry,” said Dr. Vanier. “Interest in wellness and prevention is briskly increasing and I am confident that the company is well positioned for the opportunities that lie ahead.”

As the number one personalized genetic testing provider recommended by physicians, in the last year Navigenics has also become the personal genomics testing service of choice for corporate health programs. According to the management team, the company has a considerable pipeline of corporate accounts and has begun introducing preventive genomics-based health to increasing numbers of people through employer-based partnerships. To date, the company has successfully integrated into the health and wellness programs of large, self-insured employers by offering large scale preventive genomic programs in order to increase employee motivation to improve lifestyle, enhance participation in existing employee wellness offerings, and improve medical compliance.

“It was Vance’s vision that guided Navigenics into the physician and employer wellness markets, and he has been critical to Navigenics’ success over the past two years,” said Dana G. Mead, Jr., partner at Kleiner Perkins Caufield & Byers and member of Navigenics’ Board of Directors. “As the company evolves its corporate strategy, forging deeper relationships with physician groups and employer-sponsored health and wellness programs, Vance’s clinical experience and exceptional leadership make him a natural choice to lead the company.”

“Vance has displayed an impressive commitment to getting at the heart of one of the biggest obstacles to preventive healthcare – motivating people to engage in healthy lifestyles,” said Pam Hymel, M.D. Medical Director of Cisco, President of American College of Occupational and Environmental Medicine. “But when it is successful, we have seen that every dollar spent on prevention yields three dollars in benefits. I believe that any behavior change that Navigenics can accomplish is consequently very valuable.”

ABOUT NAVIGENICS

Navigenics, Inc. is a privately held company based in Foster City, Calif. The company was founded by David Agus, M.D. and Dietrich Stephan, Ph.D., with the goal of improving health outcomes in individuals across the population. Navigenics educates and empowers individuals and their physicians with knowledge of their genetic predispositions, and then motivates them to act on the information to prevent the onset of disease, achieve earlier diagnosis, appropriately manage disease, or otherwise lessen its impact. Navigenics’ lead investors are Kleiner Perkins Caufield and Byers, Sequoia Capital and MDV-Mohr Davidow Ventures. More information can be found at www.navigenics.com.

Contact:

Navigenics, Inc. Brenna Sweeney, 650-585-7523 bsweeney@navigenics.com


Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->